{"classes":[{"categories":[{"measurements":[{"comment":"Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100.0"},{"comment":"Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}],"title":"Kaplan-Meier estimated probability of PFS ≥6 months"},{"categories":[{"measurements":[{"comment":"Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100.0"},{"comment":"Variance of Kaplan-Meier estimates cannot be calculated per Greenwood's formula when Kaplan-Meier estimates are 100% or 0% at specified time points.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}],"title":"Kaplan-Meier estimated probability of PFS ≥12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"≥6-month and ≥12-month PFS was defined as the absence of disease progression (assessed per RECIST v1.1 by the investigator) or death from any cause from the start of treatment to ≥6 or ≥12 months after treatment. A Kaplan-Meier estimate of PFS is an estimate of the probability that a participant will remain alive and free from disease progression (or relapse) at a given time point after starting treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received INCB099280 50 milligrams (mg) once daily (QD) plus adagrasib 400 mg twice daily (BID) for up to 2 years.","id":"OG000","title":"INCB099280 50 mg QD Plus Adagrasib 400 mg BID"},{"description":"Participants received INCB099280 100 mg BID plus adagrasib 400 mg BID for up to 2 years.","id":"OG001","title":"INCB099280 100 mg BID Plus Adagrasib 400 mg BID"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set. PFS rates were estimated using the Kaplan-Meier method. Confidence intervals for PFS rates were calculated using the Greenwood formula with log-log transformation.","reportingStatus":"POSTED","timeFrame":"≥6-months and ≥12-months (up to 470 days)","title":"Kaplan-Meier Estimate of ≥6-month and ≥12-month Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage probability"}